Forte Biosciences (FBRX) Assets Average (2017 - 2026)
Forte Biosciences (FBRX) posted quarterly Assets Average of $75.0 million for Q1 2026, up 37.59% year-over-year from $54.5 million in Q1 2025, and down 16.6% quarter-over-quarter from $89.9 million in Q4 2025.
Forte Biosciences (FBRX) Assets Average (2017 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Assets Average for 10 consecutive years, with $75.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 37.59% year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $75.0 million (up 37.59% YoY), while the FY2025 annual figure was $72.2 million, up 43.56% from the prior year.
- Assets Average fell to $75.0 million in Q1 2026 per FBRX's latest filing, from $89.9 million in the prior quarter.
- Across five years, Assets Average topped out at $102.4 million in Q3 2025 and bottomed at $22.0 million in Q3 2024.
- Historically, Assets Average has averaged $50.1 million across 5 years, with a median of $42.3 million in 2022.
- Annual changes were most pronounced in 2024 — Assets Average slumped 44.32% — and 2025, when it soared 365.36%.
- Forte Biosciences' Assets Average stood at $43.6 million in 2022, then decreased by 0.31% to $43.4 million in 2023, then slipped by 8.46% to $39.8 million in 2024, then soared by 126.23% to $89.9 million in 2025, then retreated by 16.6% to $75.0 million in 2026.
- Business Quant data shows FBRX's Assets Average at $75.0 million in Q1 2026, $89.9 million in Q4 2025, and $102.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 136.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136.48 Mn |
| Mar 31, 2026 | 75.00 Mn |
| Dec 31, 2025 | 89.93 Mn |
| Sep 30, 2025 | 102.44 Mn |
| Jun 30, 2025 | 77.62 Mn |
| Mar 31, 2025 | 54.51 Mn |
| Dec 31, 2024 | 39.75 Mn |
| Sep 30, 2024 | 22.01 Mn |
| Jun 30, 2024 | 29.05 Mn |
| Mar 31, 2024 | 35.50 Mn |
| Dec 31, 2023 | 43.43 Mn |
| Sep 30, 2023 | 39.53 Mn |
| Jun 30, 2023 | 33.95 Mn |
| Mar 31, 2023 | 39.35 Mn |
| Dec 31, 2022 | 43.56 Mn |
| Sep 30, 2022 | 42.42 Mn |
| Jun 30, 2022 | 40.51 Mn |
| Mar 31, 2022 | 42.31 Mn |
| Dec 31, 2021 | 45.35 Mn |
| Sep 30, 2021 | 50.14 Mn |